ProKidney Corp - Class A - fluxo de caixa trimestral (NASDAQ:PROK) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Cash from operating activities -24.17 M-29.59 M-31.42 M-26.6 M-32.51 M -120.12 M Cash from investing activities 15.08 M28.29 M18.57 M29.02 M28.09 M 103.97 M Cash from financing activities 123 K-12 K-14 K7.96 M17.63 M 25.57 M Free cash flow -49.68 M-30.73 M-34.53 M-31.79 M-38.27 M -135.31 M

Notícias

ProKidney nomeia Greg Madison como diretor comercial

BofA mantém recomendação de desempenho inferior para ProKidney com preço-alvo de US$ 1

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright inicia cobertura da ProKidney com recomendação de compra e preço-alvo de US$ 12

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Compass Minerals Intl (NYSE:CMP), MYR Group (NASDAQ:MYRG)

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

ProKidney Corp. (PROK) Presents at Morgan Stanley 23rd Annual